The meeting, held at Shohada-ye Tajrish Hospital, was attended by Mohammad Eslami, Iran’s vice president and head of the Atomic Energy Organization of Iran, alongside specialists in nuclear medicine and oncology.

The one-day event focused on recent advances in cancer diagnosis and treatment using nuclear technologies in Iran as well as the world.

Meanwhile, organizers said the scientific program covers radiopharmaceuticals as a new horizon in cancer diagnosis and therapy, diagnostic and therapeutic applications of FAPI, prostate cancer management, diagnosis and treatment of neuroendocrine tumors, and new cancer therapies using alpha-emitting radiopharmaceuticals such as radium-223 and actinium-225.

Sessions also address new treatments for non-melanoma skin cancers and the clinical use of advanced nuclear medicine techniques.

Participation in the event qualifies for continuing education credits for nuclear medicine specialists, adult hematology and oncology subspecialists, radiation oncologists, pathologists, urologists, medical physicists, cancer surgeons, dermatologists and pharmacists.

Separately, a statement issued at the opening of the first joint conference of nuclear medicine, radiation oncology, hematology and oncology specialists stressed that advances in nuclear technology and its health applications over recent decades have demonstrated the key role of nuclear methods not only in cancer prevention but also in accurate diagnosis, pain relief, improved treatment success, reduced side effects and enhanced quality of life for cancer patients.

The statement was read at the opening ceremony by the head of the Iranian Scientific Association of Nuclear Medicine.

“Cancer, as the second leading cause of death in the world and in Iran, is one of the most important challenges facing health systems in the current century and requires a comprehensive and multi-dimensional approach to prevention and treatment,” the statement said.

It added that significant progress in the production of diagnostic and therapeutic radiopharmaceuticals, as the core tools of nuclear medicine, has increased the need to review treatment approaches and update specialists’ knowledge in recent years.

The Iranian Scientific Association of Nuclear Medicine said it was hosting the meeting in cooperation with the Iranian Society of Oncology and Hematology and the national Association of Radiation Oncology, with the support of Shahid Beheshti University of Medical Sciences.

The statement concluded by expressing hope that active participation by senior academics would make the event a turning point in improving diagnostic and therapeutic services for cancer patients and help strengthen cooperation among specialists across related fields.